drugset / Trial / NCT03114319
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in adult patients with advanced solid tumors in selected indications.
Timeline
- Start
- 2017-05-26
- Primary completion
- 2025-07-04
- Completion
- 2025-07-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BATOPROTAFIB | Small molecule | — | Oral |
| Subject | Nazartinib | Small molecule | — | Oral |